Novartis AG (NVS)

85.31
NYSE : Health Care
Prev Close 85.31
Day Low/High 0.00 / 0.00
52 Wk Low/High 66.93 / 86.90
Avg Volume 2.32M
Exchange NYSE
Shares Outstanding 2.37B
Market Cap 202.85B
EPS 2.80
P/E Ratio 30.41
Div & Yield 2.72 (3.20%)

Latest News

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide

Futures lower even as crude oil rises.

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success

Novartis shares led gainers in Switzerland Thursday after the pharmaceuticals group told investors that its Canakinumab drug met its primary endpoint in phase three clinical trials.

FDA Commisoner Takes on Big Pharma

FDA Commisoner Takes on Big Pharma

Investors should watch these companies come July 18th.

The More Things Change…

… and market internals are seeing some changes.

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.

Google and Novartis Back Medicxi's New $300 Million Fund

Google and Novartis Back Medicxi's New $300 Million Fund

Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

The Reasons Kite Pharma Is Set to Fly Higher

The Reasons Kite Pharma Is Set to Fly Higher

BTIG analyst Dane Leone noted three key reasons why he executed today's upgrade of the stock.

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer

Bristol-Myers will conduct the study and both companies will evaluate the findings.

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Bluebird Bio Is Liked by Analysts, Cognizant Isn't

Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel.

Why I'm Positive on Novartis

Why I'm Positive on Novartis

Here's where to buy NVS.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENLC, NVS, RDI Downgrades: ATAI, PFSI, TICC, WMIH Initiations: GMRE, NGVT Read on to get TheStreet Quant Ratings' detailed report:

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.

Biotech Movers: Minerva, XBiotech, Aduro

Biotech Movers: Minerva, XBiotech, Aduro

Minerva Neurosciences, XBiotech and Aduro Biotech were among the biotech movers in premarket trading on Thursday.

Novartis Cautions on U.S. Pricing Pressures; Shares Edge Higher on Steady Outlook for Sandoz Sales

Novartis Cautions on U.S. Pricing Pressures; Shares Edge Higher on Steady Outlook for Sandoz Sales

Novartis shares edged higher after the Swiss drugmaker cautioned that pricing pressures in the U.S. and the delay of a multiple sclerosis therapy dosage would hit its generic division's sales.

Bristol-Myers Hookup Boosts Array BioPharma

Bristol-Myers Hookup Boosts Array BioPharma

Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.